Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPELINE: Pazopanib Resistance Biomarkers in mRCC
NCT04462445Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of pazopanib in metastatic renal cell carcinoma (mRCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Jun 2015; status: completed.
02
Drugs
pazopanib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT04462445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04462445.